U.S. FDA’s Rebuttal On Impure Atorvastatin Generics In U.S. Cheers Indian Firms
This article was originally published in PharmAsia News
Executive Summary
After a spate of criticism for supplies of substandard drugs and GMP violations, the Indian generic drug industry found support from FDA’s Center for Drugs chief, who disputed claims that atorvastatin generics sold in the United States contained impurities.